The regulation of the complement system: insights from genetically-engineered mice

被引：44

作者：

Turnberg, D ^{[1
]}

Botto, M ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Med, Rheumatol Sect, London W12 0NN, England

来源：

MOLECULAR IMMUNOLOGY | 2003年 / 40卷 / 2-4期

关键词：

complement; complement regulatory proteins; genetically modified mice;

D O I：

10.1016/S0161-5890(03)00110-X

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The complement system is very tightly regulated by fluid-phase and membrane-bound factors that prevent injury to self-tissues. The study of genetically engineered animals with targeted deletion or gain of function mutations has highlighted the important role that many of the complement inhibitors play in vivo. The advantages and disadvantages of this type of approach are discussed and the insights gained from the investigation of these animals are reviewed. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：145 / 153

页数：9

相关论文

共 107 条

[41] Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm [J].

Inoue, N ;

Ikawa, M ;

Nakanishi, T ;

Matsumoto, M ;

Nomura, M ;

Seya, T ;

Okabe, M .

MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (07) :2614-2622

[42]

Jokiranta TS, 1996, FEBS LETT, V393, P297

[43] Clusterin [J].

Jones, SE ;

Jomary, C .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (05) :427-431

[44]

KILGORE KS, 1995, J IMMUNOL, V155, P1434

[45] MOUSE COMPLEMENT REGULATORY PROTEIN CRRY/P65 USES THE SPECIFIC MECHANISMS OF BOTH HUMAN DECAY-ACCELERATING FACTOR AND MEMBRANE COFACTOR PROTEIN [J].

KIM, YU ;

KINOSHITA, T ;

MOLINA, H ;

HOURCADE, D ;

SEYA, T ;

WAGNER, LM ;

HOLERS, VM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (01) :151-159

[46] Discordant organ xenotransplantation in primates - World experience and current status [J].

Lambrigts, D ;

Sachs, DH ;

Cooper, DKC .

TRANSPLANTATION, 1998, 66 (05) :547-561

[47] Complement factor I deficiency in a family with recurrent infections [J].

Leitao, MF ;

Vilela, MMS ;

Rutz, R ;

Grumach, AS ;

Condino-Neto, A ;

Kirschfink, M .

IMMUNOPHARMACOLOGY, 1997, 38 (1-2) :207-213

[48] Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis [J].

Lin, F ;

Emancipator, SN ;

Salant, DJ ;

Medof, ME .

LABORATORY INVESTIGATION, 2002, 82 (05) :563-569

[49] Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection [J].

Lin, F ;

Kaminski, HJ ;

Conti-Fine, BM ;

Wang, W ;

Richmonds, C ;

Medof, ME .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (09) :1269-1274

[50] Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes.: Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies [J].

Lin, F ;

Fukuoka, Y ;

Spicer, A ;

Ohta, R ;

Okada, N ;

Harris, CL ;

Emancipator, SN ;

Medof, ME .

IMMUNOLOGY, 2001, 104 (02) :215-225

← 1 2 3 4 5 6 7 8 9 10 →